Main points of investment
Biopharmaceutical company in the field of innovative oncology: Deqi Pharmaceuticals is a clinical biopharmaceutical company in the Asia-Pacific region focusing on the innovation of antineoplastic drugs. The company's uniqueness comes from industry-leading R & D capabilities and a differentiated strategic approach to developing new antineoplastic therapies. The company's vision is to discover, develop and commercialize global pioneering, unique, best-of-breed therapies, treating patients without borders and improving their living standards. The company currently focuses on the areas of blood and oncology therapy with the most experienced team and the best clinical track record, aiming to bring innovative treatments to patients in the Asia-Pacific region. The company continues to adopt the combination and mutual matching R & D strategy to maximize the ability of internally coordinated pipeline assets.
Extensive and highly differentiated product pipeline: the company has strategically designed and built an innovative R & D pipeline with 12 oncology drug assets, including two advanced clinical products, four early clinical products and six preclinical products. At the same time, the company has nine ongoing clinical trials (including three initiated by researchers) and eight planned clinical trials, and has obtained 12 IND approvals in multiple jurisdictions in the Asia-Pacific region.
World-class leadership team and deep talent pool: the founder of the company, Dr. Mei, has more than 20 years of industry and academic experience, focusing on clinical research and development of oncology drugs in the United States and China. Dr. May has a distinguished track record during her tenure as global director of clinical research at Celgene. The company's management team has a wealth of experience, composed of senior executives, with their experience in multinational biopharmaceutical companies and knowledge of the local market to lead the company to success in the future.
Risk tips: the risk of failure in new product research and development, intensified market competition, higher-than-expected cost control, etc.